7-hydroxy-1H-isochromen-4(3H)-one | 1234672-73-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 7-hydroxy-1H-isochromen-4(3H)-one
• 英文别名: 7-hydroxy-1H-isochromen-4-one
• CAS: 1234672-73-1
• 化学式: C₉H₈O₃
• 分子量: 164.161
• InChiKey: DFLXETQIUHKKFR-UHFFFAOYSA-N

物化性质

• 沸点：
  394.2±42.0 °C(Predicted)
• 密度：
  1.343±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  7-hydroxy-1H-isochromen-4(3H)-one 、 氯甲基甲基醚 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 以88%的产率得到7-(methoxymethoxy)-1H-isochromen-4(3H)-one
  参考文献：
  名称：

  Analogues of (3R)-7-Hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic). Synthesis and in Vitro and in Vivo Opioid Receptor Antagonist Activity

  摘要：

  The synthesis of compounds 6, 7a,b, 8a,b, 9a,b, and 10a,b where the amino -NH- group of JDTic (3) was replaced with an aromatic =CH-, CH2, O, S, or SO group was accomplished and used to further characterize the SAR of the compound 3 class of kappa opioid receptor antagonists. All of the compounds showed subnanomolar to low nanomolar K-e values at the kappa opioid receptor. The most potent compound was 7a, where the amino -NH- group of 3 was replaced by a methylene (-CH2-) group. This compound had a K-e = 0.18 nM and was 37- and 248-fold selective for the kappa relative to the mu and delta opioid receptors, respectively. Similar to compound 3, compound 7a antagonized selective kappa agonist U50,488-induced diuresis after sc administration in rats. In contrast to 3, where kappa antagonist activity lasted for three weeks, compound 7a did not show any kappa antagonist activity after one week.

  DOI：

  10.1021/jm1004978
• 作为产物：
  描述：

  7-甲氧基-4-异二氢色原酮 在 乙硫醇钠 、 盐酸 作用下， 以 N,N-二甲基甲酰胺 、 水 为溶剂， 反应 3.0h， 以71%的产率得到7-hydroxy-1H-isochromen-4(3H)-one
  参考文献：
  名称：

  Analogues of (3R)-7-Hydroxy-N-[(1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic). Synthesis and in Vitro and in Vivo Opioid Receptor Antagonist Activity

  摘要：

  The synthesis of compounds 6, 7a,b, 8a,b, 9a,b, and 10a,b where the amino -NH- group of JDTic (3) was replaced with an aromatic =CH-, CH2, O, S, or SO group was accomplished and used to further characterize the SAR of the compound 3 class of kappa opioid receptor antagonists. All of the compounds showed subnanomolar to low nanomolar K-e values at the kappa opioid receptor. The most potent compound was 7a, where the amino -NH- group of 3 was replaced by a methylene (-CH2-) group. This compound had a K-e = 0.18 nM and was 37- and 248-fold selective for the kappa relative to the mu and delta opioid receptors, respectively. Similar to compound 3, compound 7a antagonized selective kappa agonist U50,488-induced diuresis after sc administration in rats. In contrast to 3, where kappa antagonist activity lasted for three weeks, compound 7a did not show any kappa antagonist activity after one week.

  DOI：

  10.1021/jm1004978

文献信息

• FUSED (HETERO)CYCLIC COMPOUNDS AS S1P MODULATORS
  申请人：AbbVie Deutschland GmbH & Co. KG

  公开号：US20170174672A1

  公开（公告）日：2017-06-22

  The invention relates to (hetero)cyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.

  这项发明涉及(S1P)调节剂的(杂)环化合物，包括这种化合物的药物组合物，以及在通过S1P受体介导的疾病或紊乱的治疗、缓解或预防中的用途。
• KAPPA OPIOID RECEPTOR LIGANDS
  申请人：CARROLL Frank Ivy

  公开号：US20110065743A1

  公开（公告）日：2011-03-17

  Kappa opioid receptor antagonists are provided that yield significant improvements in functional binding assays to kappa opioid receptors, and the use of these antagonists in treatment of disease states that are ameliorated by binding of the kappa opioid receptor such as heroin or cocaine addictions.

  提供了Kappa阿片受体拮抗剂，可在功能性结合测定中显著改善对Kappa阿片受体的结合，并将这些拮抗剂用于治疗因结合Kappa阿片受体而改善的疾病状态，例如海洛因或可卡因成瘾。
• Fused (hetero)cyclic compounds as S1P modulators
  申请人：AbbVie Deutschland GmbH & Co. KG

  公开号：US10280159B2

  公开（公告）日：2019-05-07

  The invention relates to (hetero)cyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.

  本发明涉及作为 S1P 调节剂的（杂）环化合物、包含此类化合物的药物组合物及其在治疗、缓解或预防由 S1P 受体介导的疾病或紊乱中的用途。
• BICYCLIC COMPOUND
  申请人：TOA Eiyo Ltd.

  公开号：EP2840076B1

  公开（公告）日：2017-10-25
• US7872023B2
  申请人：——

  公开号：US7872023B2

  公开（公告）日：2011-01-18